A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors

Completed · Phase 1

Conditions studied: Solid Tumors

In brief

This study will evaluate toxicity associated with escalating doses of rBBX-01 given bi-weekly to patients with solid tumors.

Key facts

Study ID

NCT00869388

Run by

Washington University School of Medicine

People needed

12

Starts

2008-10-01

Expected to finish

2009-12-01

Last updated by the study team

2013-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed metastatic or unresectable, resistant solid tumor. Gynecologic tumors preferred.
• 18 years and above
• GOG performance status greater than or equal to 2
• Life expectancy greater than 6 months
• Acceptable organ and marrow function
• Willingness to agree to use adequate contraception prior to study entry and for the duration of study participation

You may not qualify if…

• Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or have not recovered from adverse events due to agents administered more than 4 weeks earlier
• Not receiving any other investigational agents
• Known brain metastasis
• Uncontrolled intercurrent illness including, but not limited to ongoing ore active infection, symptomatic congestive heart failure, unstable angina pectoris,cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnancy
• Immunosuppression including subjects with known HIV infection on immunosuppressive drugs or having an autoimmune disorder
• Penicillin allergy
• Symptomatic prostate hypertrophy

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.